The latest breaking news, delivered straight to your email!

Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

That’s perhaps the best way to describe how the undermanned squad looks at this stage of the season. But fortunately — or unfortunately — for the Sixers, the struggling Jazz are in worse shape and in ...

Jazz has earned the top place in key categories in Opensignal’s latest Mobile Network Experience Report, highlighting the digital operator’s leadership in coverage and connectivity.

Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total ...

Pakistani telco firm Jazz has partnered with Chinese tech giant Huawei to install solar panels at 1,000 mobile base stations across Pakistan. The deal, announced at Mobile World Congress, will see ...

Truist Financial analyst Joon Lee maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $230.00. See what stocks are receiving Strong Buy ...

For more than a century, Times Union photographers have been documenting the Capital Region’s fascinating people, places and pivotal moments. About Contact Services Account ...